行情

BIOC

BIOC

Biocept
NASDAQ

实时行情|Nasdaq Last Sale

0.3540
+0.0065
+1.87%
已收盘, 19:06 01/21 EST
开盘
0.3600
昨收
0.3475
最高
0.3600
最低
0.3475
成交量
359.93万
成交额
--
52周最高
2.500
52周最低
0.2275
市值
1,685.69万
市盈率(TTM)
-0.1327
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BIOC 新闻

  • Biocept validates liquid biopsy tests in cerebrospinal fluid; shares up 19%
  • seekingalpha.01/14 19:52
  • Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
  • PR Newswire.01/14 13:05
  • How Does Investing In Biocept, Inc. (NASDAQ:BIOC) Impact The Volatility Of Your Portfolio?
  • Simply Wall St..01/12 13:22
  • 【美股盘前】欧美股指期指全线上涨,日本家庭对经济的信心降至五年来最低点
  • 每日经济新闻.01/09 10:52

更多

所属板块

医疗设备、用品及经销
+0.67%
医疗设备和用品
+0.43%

热门股票

名称
价格
涨跌幅

BIOC 简况

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
展开

Webull提供Biocept Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。